Aardvark Therapeutics (NASDAQ:AARD) Now Covered by Analysts at Cantor Fitzgerald

Cantor Fitzgerald started coverage on shares of Aardvark Therapeutics (NASDAQ:AARD) in a research note released on Monday morning, MarketBeat.com reports. The brokerage issued an overweight rating and a $50.00 target price on the stock.

Aardvark Therapeutics Trading Up 1.3 %

AARD opened at $10.26 on Monday. Aardvark Therapeutics has a 1 year low of $9.21 and a 1 year high of $19.58.

Insider Buying and Selling

In other news, CEO Tien-Li Lee acquired 16,542 shares of Aardvark Therapeutics stock in a transaction on Friday, February 14th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $264,672.00. Following the completion of the purchase, the chief executive officer now directly owns 1,496,175 shares of the company’s stock, valued at approximately $23,938,800. This represents a 1.12 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Nelson Sun purchased 10,000 shares of Aardvark Therapeutics stock in a transaction that occurred on Friday, February 14th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $160,000.00. Following the transaction, the chief financial officer now directly owns 99,484 shares in the company, valued at $1,591,744. This represents a 11.18 % increase in their position. The disclosure for this purchase can be found here.

About Aardvark Therapeutics

We are a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. We target biological pathways associated with alleviating hunger that we believe have the potential to deliver transformative outcomes for patients.